North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.
作者信息
Eccles M, Freemantle N, Mason J
机构信息
Centre for Health Services Research, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4AA.
出版信息
BMJ. 1998 Apr 25;316(7140):1303-9. doi: 10.1136/bmj.316.7140.1303.
Abstract
摘要
相似文献
1
North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.
BMJ. 1998 Apr 25;316(7140):1303-9. doi: 10.1136/bmj.316.7140.1303.
2
Aspirin for prevention of myocardial infarction and stroke.
Med Lett Drugs Ther. 1989 Aug 25;31(799):77-9.
3
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Cochrane Database Syst Rev. 2003(1):CD001820. doi: 10.1002/14651858.CD001820.
4
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
Ugeskr Laeger. 2008 Mar 31;170(14):1147-51.
5
Cardiology update. Aspirin.
Nurs Stand. 1994;8(49):52-3. doi: 10.7748/ns.8.49.52.s49.
6
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Cochrane Database Syst Rev. 2006 Apr 19(2):CD001820. doi: 10.1002/14651858.CD001820.pub2.
7
Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration.
Br Med J (Clin Res Ed). 1988 Jan 30;296(6618):320-31.
8
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Cochrane Database Syst Rev. 2007 Jul 18(3):CD001820. doi: 10.1002/14651858.CD001820.pub3.
9
Is ticlopidine more effective than aspirin in preventing adverse cardiovascular events after myocardial infarction (MI)?
J Fam Pract. 2001 Jul;50(7):623.
10
[Clinical studies of the effectiveness of aspirin in the prevention of major cardio-cerebrovascular occurrences].
Cardiologia. 1995 Dec;40(12 Suppl 1):423-8.
引用本文的文献
1
Regulations of the key mediators in inflammation and atherosclerosis by aspirin in human macrophages.
Lipids Health Dis. 2010 Feb 6;9:16. doi: 10.1186/1476-511X-9-16.
2
The clinical and economic impact of a secondary heart disease prevention clinic jointly implemented by a practice nurse and pharmacist.
Pharm World Sci. 2003 Dec;25(6):294-8. doi: 10.1023/b:phar.0000006526.55922.8d.
3
Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study.
J Epidemiol Community Health. 2003 Feb;57(2):134-40. doi: 10.1136/jech.57.2.134.
4
Pharmacological treatment of elderly patients with acute coronary syndromes without persistent ST segment elevation.
Drugs Aging. 2002;19(9):633-46. doi: 10.2165/00002512-200219090-00002.
5
A randomised controlled trial of the effect of educational outreach by community pharmacists on prescribing in UK general practice.
Br J Gen Pract. 2002 Apr;52(477):290-5.
6
Developing valid cost effectiveness guidelines: a methodological report from the north of England evidence based guideline development project.
Qual Health Care. 2000 Jun;9(2):127-32. doi: 10.1136/qhc.9.2.127.
7
Extrapolation of trial results suggests that aspirin is useful in intermittent claudication.
BMJ. 1998 Dec 5;317(7172):1587-8. doi: 10.1136/bmj.317.7172.1587a.
8
Aspirin prophylaxis for vascular disease. Knowledge needs to be used in clinical situations.
BMJ. 1998 Nov 7;317(7168):1318; author reply 1319. doi: 10.1136/bmj.317.7168.1318a.
9
North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care.
BMJ. 1998 Apr 18;316(7139):1232-5. doi: 10.1136/bmj.316.7139.1232.
本文引用的文献
1
North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care.
BMJ. 1998 Apr 18;316(7139):1232-5. doi: 10.1136/bmj.316.7139.1232.
2
Who needs antiplatelet therapy?
Br J Gen Pract. 1996 Jun;46(407):367-70.
3
Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group.
Circulation. 1993 May;87(5):1563-9. doi: 10.1161/01.cir.87.5.1563.
4
The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials.
Br J Clin Pharmacol. 1993 Mar;35(3):219-26. doi: 10.1111/j.1365-2125.1993.tb05689.x.
5
Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial.
Eur Heart J. 1993 Jul;14(7):951-7. doi: 10.1093/eurheartj/14.7.951.
6
7
The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group.
Circulation. 1980 Dec;62(6 Pt 2):V79-84.
8
The anturane reinfarction trial.
Circulation. 1980 Dec;62(6 Pt 2):V73-8.
9
Aspirin and secondary mortality after myocardial infarction.
Circulation. 1980 Dec;62(6 Pt 2):V53-8.
10
The FDA's critique of the anturane reinfarction trial.
N Engl J Med. 1980 Dec 18;303(25):1488-92. doi: 10.1056/NEJM198012183032534.
Zotero 插件